Skip to main content

Ex‑OpenAI Science Head Kevin Weil Launches Warp Sciences with $215 M Funding

Ex‑OpenAI Science Head Kevin Weil Launches Warp Sciences with $215 M Funding

THE TECH CHRONICLE  ·  technology  ·  Friday, October 23, 2026
Ex‑OpenAI Science Head Kevin Weil Launches Warp Sciences with $215 M Funding

The company, founded by former OpenAI science chief Kevin Weil, aims to bring a fully automated, AI‑driven chemistry lab to the U…

By TechPulse Blog

Warp Sciences emerged from stealth on Thursday after securing $215 million in a Series A round led by Lightspeed Venture Partners, valuing the startup at $865 million. The company, founded by former OpenAI science chief Kevin Weil, aims to bring a fully automated, AI‑driven chemistry lab to the United States, targeting the drug‑optimization step traditionally outsourced to Chinese contract manufacturers such as WuXi AppTec.

Key Takeaways

  • Warp Sciences raised $215 million, led by Lightspeed, with a post‑money valuation of $865 million.
  • The startup will operate a robotic, AI‑enhanced lab in the U.S. to replace China‑based contract chemistry services.
  • Founders include AI veterans Manohar Paluri (Meta), DJ Patil (White House), and Solomon Reisberg (Terremoto Biosciences).
  • Investors span venture firms (IVP, Premji Invest, Lux Capital) and angels such as Sarah Friar, Brian Armstrong, and Reid Hoffman.
  • Warp’s initial team of ~20 has already equipped the lab with robotic arms and AI accelerators, while chemists collect sensor‑rich data for model training.
Metric Value Why it matters
Founder / Former role Kevin Weil – former head of OpenAI’s Science unit Provides deep AI expertise and credibility in scientific AI applications.
Series A funding $215 million Signals strong investor confidence in AI‑driven drug‑development infrastructure.
Post‑money valuation $865 million Places Warp among the most highly valued early‑stage AI biotech startups.
Lead investor Lightspeed Venture Partners Lightspeed’s involvement brings strategic guidance and a track record in scaling AI companies.

What Warp Sciences Is Building

Warp’s core proposition is an end‑to‑end, automated chemistry platform that can synthesize, test, and iterate on thousands of molecular variants without human hands. The lab’s robotic arms handle liquid handling and compound mixing, while on‑board AI chips run inference on proprietary models that predict reaction outcomes, yield, and toxicity. Chemists wear camera‑equipped goggles and pressure‑sensing gloves, feeding high‑resolution visual and tactile data back into the training loop.

“It’s still an area where frontier AI models are not yet changing the world in the way models are changing the world in software engineering and math,” Weil said. “That’s because the field is so much more experimentally driven. The models need to see that data.”

Funding, Leadership, and Investor Landscape

Lightspeed led the round, with participation from IVP, Premji Invest, and Lux Capital. Angel investors include OpenAI’s former CFO Sarah Friar, Coinbase CEO Brian Armstrong, and LinkedIn co‑founder Reid Hoffman. The co‑founding team adds depth: Manohar Paluri previously ran Meta’s Superintelligence Labs, DJ Patil served as the White House’s first chief data scientist, and Solomon Reisberg brings experience from Terremoto Biosciences. This blend of AI research, data‑science policy, and biotech execution mirrors the talent mix we’ve seen in other recent AI‑drug ventures.

Strategic Context: Reducing Dependence on Chinese Contract Chemists

Pharma companies have long outsourced the “medicinal chemistry optimization” phase to firms like WuXi AppTec because of lower cost and faster turnaround. However, rising U.S.–China geopolitical tension—highlighted by the Pentagon’s brief inclusion of WuXi AppTec on a list of entities linked to the Chinese military—has made that reliance riskier. A federal judge blocked the designation in August, but the episode underscored concerns about data security and supply‑chain resilience. Warp’s U.S.‑based, AI‑controlled lab directly addresses those worries by keeping proprietary molecular data on domestic soil.

AI in Drug Discovery: Where Warp Fits

Warp is not a drug‑discovery engine; it focuses on the downstream optimization stage after a lead compound is identified. This differentiates it from companies like Chai Discovery, which raised $400 million in July to use generative AI for early‑stage hit identification, and from OpenAI’s recent acquisition of Orchestra Bio, an AI‑agent platform for managing end‑to‑end drug pipelines. The market is seeing parallel moves: Arda, founded by former OpenAI leader Bob McGrew, secured $232 million for AI‑driven factory line setup, and OpenAI researcher Miles Wang is reportedly courting $200 million for his own drug‑startup venture.

Why It Matters

Warp Sciences represents a concrete step toward domesticizing a critical, cost‑intensive segment of pharmaceutical R&D. By marrying robotics with frontier AI models trained on sensor‑rich experimental data, the startup could compress weeks of manual synthesis into hours of automated runs, potentially lowering development costs and accelerating time‑to‑clinic. For investors, the $215 million raise and $865 million valuation signal that capital markets view AI‑enabled lab automation as a high‑impact frontier. For the broader industry, the move may trigger a shift away from offshore contract chemistry, reshaping global supply chains and data‑privacy practices.

Frequently asked questions

Who founded Warp Sciences and what are their backgrounds?

Warp was founded by Kevin Weil, the former head of OpenAI’s Science unit. Co‑founders include Manohar Paluri (ex‑Meta Superintelligence Labs VP), DJ Patil (the White House’s first chief data scientist), and Solomon Reisberg (formerly of Terremoto Biosciences).

How much capital has Warp raised and at what valuation?

The company closed a $215 million Series A round led by Lightspeed Venture Partners, bringing its post‑money valuation to $865 million.

What specific problem is Warp trying to solve?

Warp aims to automate the medicinal‑chemistry optimization step—where hundreds to thousands of molecular variants are synthesized and tested—by building a U.S.‑based robotic lab that feeds high‑fidelity experimental data into AI models.

Which investors are backing the startup?

Beyond Lightspeed, the round included IVP, Premji Invest, Lux Capital, and angel investors Sarah Friar, Brian Armstrong, and Reid Hoffman.

How does Warp differ from other AI‑driven drug companies?

Unlike firms that focus on early‑stage hit generation, Warp does not discover new drugs. Instead, it accelerates the downstream optimization of already identified leads, a niche that has traditionally been outsourced to contract manufacturers in China.

Bottom Line

Warp Sciences has marshaled a heavyweight investor slate and a team of AI and biotech veterans to launch a domestic, AI‑powered chemistry lab that could reshape how pharmaceutical companies refine candidate molecules. The $215 million infusion and $865 million valuation underscore market belief that automating this experimentally intensive step is both feasible and strategically valuable amid growing U.S.–China supply‑chain concerns.

We’ll be watching how quickly Warp can translate its robotic platform into measurable reductions in cycle time and cost for partner pharma firms.

Reporting based on: original source.

Comments

Popular posts from this blog

Tracking your plastic: Exposing recycling myths

Tracking your plastic: Exposing recycling myths Marketplace journalists go undercover overseas and pose as recycling brokers to expose the lucrative plastic recycling business. We reveal that Malaysian companies are willing to break the law to buy Canadian plastic and show how some of it is dumped and burned in illegal landfills, where the toxic fumes and run-off appear to be making people sick. Back in Canada, we buy nine tonnes of plastic and secretly track where big companies are taking it. Will it actually get recycled? »»» Subscribe to CBC News to watch more videos: http://bit.ly/1RreYWS Connect with CBC News Online: For breaking news, video, audio and in-depth coverage: http://bit.ly/1Z0m6iX Find CBC News on Facebook: http://bit.ly/1WjG36m Follow CBC News on Twitter: http://bit.ly/1sA5P9H For breaking news on Twitter: http://bit.ly/1WjDyks Follow CBC News on Instagram: http://bit.ly/1Z0iE7O Download the CBC News app for iOS: http://apple.co/25mpsUz Download the CBC News app for ...

Red states now legalizing recreational marijuana too

Red states now legalizing recreational marijuana too The 2020 election proved how broadly accepted recreational marijuana has become throughout the US and across party lines, with measures to legalize recreational pot breezing to victories in Arizona, New Jersey, Montana and South Dakota. (Nov. 12) Subscribe for more Breaking News: https://ift.tt/18F6bii Website: https://apnews.com Twitter: https://twitter.com/AP Facebook: https://ift.tt/2Nv6Z1g Google+: https://ift.tt/seidce Instagram: https://ift.tt/2G5Qog8 ​ You can license this story through AP Archive: https://ift.tt/2ImtqJ5

Two virus survivors get double lung transplants

Two virus survivors get double lung transplants A young paralegal and a car mechanic received lifesaving double lung transplants at Northwestern Medicine in Chicago after COVID-19 destroyed their lungs. (July 30) Subscribe for more Breaking News: https://ift.tt/18F6bii Website: https://apnews.com Twitter: https://twitter.com/AP Facebook: https://ift.tt/2Nv6Z1g Google+: https://ift.tt/seidce Instagram: https://ift.tt/2G5Qog8 ​ You can license this story through AP Archive: https://ift.tt/310Ng1O